Funded by the NIH HEAL Initiative®
This study will examine if rapid transition to extended release naltrexone (XR-NTX) following detoxification yields a higher proportion of patients successfully receiving the first injection of XR-NTX compared to standard detoxification and naltrexone initiation and will assess facilitators and barriers to implementing rapid XR-NTX initiation.
Principal Investigator(s)
Adam Bisaga, M.D.
1051 Riverside Drive, Unit 120
New York, NY 10032
United States
Edward V. Nunes, Jr., M.D.
1051 Riverside Drive
Unit 51, Room 3717
New York, NY 10032
United States